DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...